Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 7, Number 9, September 2015, pages 694-699

Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes

Figures

Figure 1.
Figure 1. Changes in clinical parameters for 24 weeks after liraglutide treatment in 57 patients: (a) HbA1c (NGSP); (b) 2 h postprandial plasma glucose; (c) body weight.
Figure 2.
Figure 2. Changes in HbA1c (NGSP), 2 h postprandial plasma glucose for 24 weeks by different liraglutide doses received: 0.6 mg (n = 22) or 0.9 mg (n = 35). **P < 0.001, *P < 0.05 compared with the values at baseline.
Figure 3.
Figure 3. Changes in HbA1c (NGSP), 2 h postprandial plasma glucose for 24 weeks after liraglutide introduction by body mass index difference: less than 25 (n = 19), 25 to 29 (n = 19), or over 30 (n = 19). **P < 0.001, *P < 0.05 compared with the values at baseline.
Figure 4.
Figure 4. Changes in HbA1c (NGSP), 2 h postprandial plasma glucose for 24 weeks after liraglutide introduction by difference in duration of diabetes: less than 10 years (n = 23) or over 10 years (n = 34). **P < 0.001, *P < 0.05 compared with the values at baseline.
Figure 5.
Figure 5. Changes in HbA1c (NGSP), 2 h postprandial plasma glucose for 24 weeks after liraglutide introduction by difference in SU index (glimepiride dose in mg × number of years of administration): over 5 (n = 27) or less than 5 (n = 30). **P < 0.001, *P < 0.05 compared with the values at baseline.

Table

Table 1. Baseline Characteristics
 
Number of subjects (male/female)30/27
Age (years)58.0 ± 12.0
Duration of diabetes (years)10.6 ± 6.3
Body weight (kg)72.1 ± 18.6
BMI (kg/m2)27.9 ± 5.9
HbA1c (NGSP) (%)9.5 ± 1.6
2 h postprandial plasma glucose (mg/dL)230.2 ± 83.3
2 h postprandial CPR (ng/mL)3.3 ± 2.0